A Multi-Stakeholder Partnership for Better Obesity Trials
The DIA Obesity Consortium is a multi-stakeholder public-private partnership dedicated to improving the efficiency and impact of obesity clinical trials. Building on a shared commitment to advancing clinically meaningful outcomes, the consortium works to standardize endpoints, optimize trial design, and explore innovative approaches that may address multiple indications within a single development program.
Now in Phase II, the consortium brings together more than 60 experts from 11 organizations to turn the alignment reached with FDA and EMA in Phase I into practical resources for endpoint measurement and multi-indication trial design.
Through structured dialogue and collaboration among regulators, industry leaders, academic and nonprofit experts, payers, and patients, the consortium defines and maps the optimal path forward for the field—accelerating scientific progress while maintaining rigor and relevance.
Addressing Critical Gaps in Obesity Clinical Development
This work benefits the life sciences community by building consensus around standardized, fit-for-purpose clinical measures and endpoints that will reduce development inefficiencies, strengthen regulatory review, and accelerate patient access to safe, effective obesity therapies worldwide.
Addressing fragmentation and variability in obesity clinical trial design, endpoints, and outcome measures that limit comparability and regulatory confidence.
Supporting more efficient, scientifically rigorous, and patient-relevant trials that better inform regulatory and clinical decision-making.
Advancing collaboration among regulators, industry, academic researchers, nonprofits, and patients to align on what constitutes clinically meaningful benefit in obesity.
Working Groups
Two focused working groups deliver coordinated outputs to improve Phase 3 obesity trial design and endpoint standardization.
Focused on building consensus around what, how, and when to measure label-enabling efficacy endpoints in Phase 3 obesity trials, with particular attention to body composition, physical function, and muscle preservation as indicators of meaningful weight loss.
Centered on identifying efficient clinical trial designs to support multiple obesity-related indications, including prioritization of key comorbidities, use of multi-endpoint or single-trial approaches, and evaluation of surrogate endpoints to reduce reliance on standalone outcome studies.
Key Activities and Status
From stakeholder formation to published consensus, a structured pathway from expert insight to measurable global impact.
Initial stakeholder engagement to assess alignment, define priorities, and establish the strategic framework for the DIA Obesity Consortium.
Convened an Executive Roundtable on April 24, 2025 in Gaithersburg, MD with FDA participation, followed by a presentation of key themes at the DIA 2025 Global Annual Meeting on June 18, 2025 in Washington, DC. Insights were published in the September 2026 issue of Global Forum: Obesity Drug Development: Time to Revisit Endpoints, Trial Design, and Evidence Generation.
Launched the consortium with 10 member companies and two working groups to build consensus on clinically meaningful endpoints and multi-indication trial design. Included the DIA European Executive Roundtable on Obesity Drug Development, held with EMA participation on March 23, 2026 in Rotterdam.
Presented Phase I outcomes at the DIA 2026 Global Annual Meeting on June 16, 2026 in Philadelphia, PA.
Published back-to-back Executive Roundtable manuscripts in Global Forum: Obesity Drug Development: Time to Revisit Endpoints, Trial Design, and Evidence Generation (September 2026) and Generating Label-Enabling Endpoint Data (October 2026).
Expanded to more than 60 experts from 11 member organizations. Phase II turns Phase I consensus into practical tools for endpoint measurement and multi-indication trial design, with continued engagement with FDA, EMA, and other global regulators.
Co-Chairs and Advisory Committee
The consortium draws on expertise and guidance from across industry, regulatory agencies, academia, medical experts, and patient advocacy organizations.
Working Group 1
- Julia Luan, AstraZeneca
- Alison Matsui, Genentech / Roche
- Jenny Blau, Regeneron
- Brad Jordan, Eli Lilly and Company
Working Group 2
- Katherin Ruiz, Eli Lilly and Company
- Jill Lee, Novo Nordisk
- Kathleen Waldron, AbbVie







Key Deliverables
The consortium generates practical, consensus-driven resources to inform obesity clinical development, regulatory engagement, and evidence-generation strategies worldwide. Phase I results are now published, and Phase II builds on them.
A consensus-based Core Clinical Endpoint Set to support standardized Phase 3 obesity trials across global regulatory regions.
Recommendations on standardized approaches to measuring body composition and physical function as indicators of meaningful weight loss.
Frameworks for more efficient clinical trial designs, including master and basket protocols, that address obesity and priority comorbidities in a single development program.
Two Executive Roundtable manuscripts published in Global Forum (Obesity Drug Development: Time to Revisit Endpoints, Trial Design, and Evidence Generation, September 2026, and Generating Label-Enabling Endpoint Data, October 2026), with more publications, presentations, and a webinar planned in Phase II.
Benefits of Membership
Participation is open to pharmaceutical and biotechnology companies, regulatory agencies, academic researchers, nonprofit organizations, patient advocacy groups, and other stakeholders engaged in obesity research and clinical development.










